Innova Captab Ltd Q2 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/b8pbq2jsoc3zleisv5yzj1xo.pdf

Key Takeaways


Jammu Facility: The Growth Engine

Lohariwala: "But in Jammu, what is the beauty that we have the 12% GST incentive, right? So our expectation is that after Q4, means even in Q4, there may be some lag. But from the Q1 next year, we will be - we will cross the break-even level and start positive EBITDA generation from the Q1 next financial year."

CDMO: The Turnaround Quarter

Lohariwala: "If you see our domestic CDMO business, you will find there are only few companies who have crossed the thousand crores mark, right? So, now as you see that the regulator also has imposed a lot of things like the revised Schedule M and now the pharma plant is like a big investment."

Branded Generics & Sharon: The Steady Compounders


Margins & Capital Allocation

Bhasin: "So the way I am looking at it, so when I am able to reach at a steady-state of Jammu, somewhere in the range of 700 crores to 900 crores, we should be positively looking at a benefit on margin expansion."

Competitive Position & Industry Structure

Lohariwala: "As most of our facility is having SRA approvals like EUGMP or MHRA or WHO-GMP, so we are complying with all these guidelines. So, we see it as a positive trigger. The industry will further consolidate to the larger players due to this implementation of the sticker norms."

Guidance & Commitments

CommitmentSpecificsTimeline
Jammu commercializationAll four blocks commence operations togetherQ3 FY25 (December)
Jammu break-evenCross break-even, positive EBITDA generation beginsQ1 FY26
Jammu FY26 revenue~₹400-500 cr salesFY26
Jammu steady-state margin expansionPositive margin expansion benefit when Jammu reaches ₹700-900 cr revenueNo specific date given
Jammu long-term revenue potential₹1,200-1,300 crNext five years
Consolidated revenue targetDouble from ~₹1,085 cr to ₹2,500 cr (25%+ CAGR)Next three years
Long-term EBITDA margin17-19% at steady state when Jammu is stabilizedWhen Jammu stabilized
Domestic branded generic growth20-25%+ growthNear future
Gross margin range32-35%Ongoing
Cash deploymentAcquisition (hormone/liquid injectable) or greenfield projectNo specific timeline

Key Metrics

MetricQ2 FY25
Consolidated revenue₹318.2 cr, +12.5% YoY
CDMO revenue₹165.1 cr, +10% YoY, volume-driven with stable pricing
Domestic branded generic revenue₹59.1 cr, +19% YoY, highest-ever quarterly revenue
International branded generic revenue₹40.5 cr, +13% YoY
Sharon revenue₹53.6 cr, +11% YoY
EBITDA₹51.9 cr, +18.6% YoY; margin 16.3%, +80 bps YoY
PAT₹35 cr, +52.8% YoY; PAT margin 11%, +290 bps YoY
H1 FY25 consolidated revenue₹612.5 cr, +19% YoY
H1 FY25 EBITDA₹96.2 cr, +26.2% YoY; margin 15.7% vs 14.8% in H1 FY24
H1 FY25 PAT₹64.5 cr, +59% YoY
Business mixCDMO ~52%, Domestic branded generics ~19%, International ~13%, Sharon ~17%
Gross margin range (post-consolidation)32% to 35%, up from 24% to 28% standalone historically
Long-term EBITDA margin target17% to 19%, at steady-state with Jammu stabilized
Jammu facility capex~₹450 cr, CWIP of ₹452 cr as of Sep 30
Jammu facility revenue potential₹1,200 cr – ₹1,300 cr over next five years
Jammu facility expected FY26 revenue₹400 cr – ₹500 cr, incremental to existing business
Revenue target (three-year)₹2,500 cr, doubling from ~₹1,085 cr, implying ~26% CAGR
CDMO client base190+ companies, including 14 of top 15 pharma companies
Domestic branded generic network1.5 lakh touch points, 600+ products
International registrations148 active, 72 in-process product dossiers across 25+ countries
Sharon capacity utilization45% to 50% (formulation), optimum range 70% to 75%
Jammu term loan₹230 cr, net landed interest cost post-commercialization at 2% to 2.5% after 6% interest subvention
Jammu GST incentive12% on domestic sales, applicable to arm's-length sales including to Univentis